In short
Elenestinib (BLU-263) is an investigational drug being studied in clinical trials for the treatment of various forms of systemic mastocytosis, a rare blood disorder characterized by the abnormal accumulation of mast cells in different organs. These trials aim to evaluate the safety, efficacy, and optimal dosing of elenestinib in patients with advanced systemic mastocytosis (AdvSM) and indolent systemic mastocytosis (ISM), as well as its potential use in combination with other therapies.
At a glance
- Drug Name
- Elenestinib (BLU-263)
- Conditions Studied
- Advanced Systemic Mastocytosis (AdvSM), Indolent Systemic Mastocytosis (ISM), Smoldering Systemic Mastocytosis (SSM)
- Trial Phases
- Phase 1/2 and Phase 2/3
- Administration
- Oral, film-coated tablets
- Treatment Arms
- Monotherapy and combination therapy with azacitidine
- Primary Objectives
- Determine recommended dose, assess safety and tolerability, evaluate efficacy
- Secondary Objectives
- Assess overall response rate, pharmacokinetics, quality of life measures
- Key Inclusion Criteria
- Confirmed diagnosis of SM, presence of KIT D816V mutation, moderate to severe symptoms
- Key Exclusion Criteria
- Other myeloproliferative disorders, significant cardiovascular disease, prior treatment with selective KIT inhibitors
- Trial Duration
- Up to 4 years, including long-term follow-up
What is BLU-263 (Elenestinib)?
BLU-263, also known as Elenestinib, is an investigational drug being developed by Blueprint Medicines for the treatment of various blood disorders. It is a selective KIT inhibitor, which means it targets a specific protein called KIT that is often mutated in certain blood cancers.
What Conditions Does BLU-263 Treat?
BLU-263 is being studied for the treatment of several conditions, including:
- Advanced Systemic Mastocytosis (AdvSM): A rare blood disorder characterized by the accumulation of abnormal mast cells in various organs.
- Indolent Systemic Mastocytosis (ISM): A less aggressive form of systemic mastocytosis.
- Smoldering Systemic Mastocytosis (SSM): An intermediate form of systemic mastocytosis.
- Other KIT-altered hematologic malignancies: Blood cancers that have mutations in the KIT gene.
How Does BLU-263 Work?
BLU-263 works by targeting and inhibiting the KIT protein, particularly when it has a specific mutation called D816V. This mutation is commonly found in systemic mastocytosis and some other blood cancers. By blocking the activity of the mutated KIT protein, BLU-263 aims to stop the growth and spread of abnormal cells.
Clinical Trials and Research
BLU-263 is currently being studied in several clinical trials:
- AZURE Study (BLU-263-2101): This is a Phase 1/2 study evaluating BLU-263 as both a monotherapy and in combination with azacitidine for patients with advanced systemic mastocytosis and other KIT-altered blood cancers.
- HARBOR Study: This is a Phase 2/3 study investigating BLU-263 for patients with indolent systemic mastocytosis.
These studies aim to determine the safety, efficacy, and optimal dosing of BLU-263 for different patient populations.
Dosage and Administration
BLU-263 is administered orally as a film-coated tablet. The exact dosage is still being determined through clinical trials, but current studies are exploring doses ranging from 25 mg to 100 mg daily. The medication is typically taken once daily, but the optimal dosing schedule may vary depending on the specific condition being treated and individual patient factors.
Potential Side Effects
As BLU-263 is still in clinical trials, the full range of potential side effects is not yet known. However, common side effects of targeted therapies like BLU-263 may include:
- Nausea and vomiting
- Fatigue
- Diarrhea
- Changes in blood cell counts
- Skin reactions
The ongoing clinical trials are closely monitoring patients for any adverse events to better understand the safety profile of BLU-263.
Patient Eligibility
Eligibility for BLU-263 treatment or clinical trials may include:
- Confirmed diagnosis of advanced systemic mastocytosis, indolent systemic mastocytosis, or other KIT-altered blood cancers
- Presence of the KIT D816V mutation
- Age 16 or older (18 or older in some countries)
- Adequate organ function
- No recent treatment with certain other medications
Specific eligibility criteria may vary depending on the particular clinical trial or treatment protocol.
Future Prospects
BLU-263 (Elenestinib) shows promise as a potential treatment for various forms of systemic mastocytosis and other KIT-altered blood cancers. If the ongoing clinical trials demonstrate favorable results, it could provide a new targeted therapy option for patients who may not have responded well to existing treatments. As research continues, more information about the efficacy, safety, and optimal use of BLU-263 will become available, potentially leading to its approval as a new treatment for these challenging blood disorders.